What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?

Robert E.J. Ryder; Ralph A. Defronzo; Bob Ryder

doi:10.15277/bjd.2017.136

What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?

Robert E.J. Ryder
, Ralph A. Defronzo
, Bob Ryder

Division of Diabetes

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	89-92
Number of pages	4
Journal	British Journal of Diabetes and Vascular Disease
Volume	17
Issue number	3
DOIs	https://doi.org/10.15277/bjd.2017.136
State	Published - 2017

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.15277/bjd.2017.136

Cite this

What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? / Ryder, Robert E.J.; Defronzo, Ralph A.; Ryder, Bob.
In: British Journal of Diabetes and Vascular Disease, Vol. 17, No. 3, 2017, p. 89-92.

Research output: Contribution to journal › Review article › peer-review

@article{fbd72357bb3c4cd590da6481e79de491,

title = "What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?",

author = "Ryder, \{Robert E.J.\} and Defronzo, \{Ralph A.\} and Bob Ryder",

year = "2017",

doi = "10.15277/bjd.2017.136",

language = "English (US)",

volume = "17",

pages = "89--92",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",